How have the shares performed?
Oncolytics Biotech Inc. (ONCY) saw an uptrend of 4.74% in the recent trading with $2.87 being its most recent. The current price level -40.58% lower than the highest price of $4.83 marked by the stock while trading over the past 52-weeks, whereas it is 88.82% higher than the lowest price of $1.52 the company dropped to over past 52-weeks. The latest news story on ONCY appeared in PR Newswire under the title “Oncolytics Biotech® to Participate in Virtual Fireside Chat at the 2021 RBC Capital Markets Global Healthcare Conference” on May-13-21.
Squeezing the time span to 30 day period shows us the stock is currently trading -8.31% below one month high and is +11.24% above of the lowest during that time. Looking into the simple moving average, Oncolytics Biotech Inc. (ONCY)’s stock stands at a SMA-50 of $3.21 while that of 5-day is reading $2.70.
Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and ONCY’s SMA-200 as of now is $2.57.
Oncolytics Biotech Inc. Earnings – What Happened With ONCY
Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor.
ONCY – Oncolytics Biotech Inc. Stock Earnings Estimates
Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 52.77 million. ONCY does have institutional investors; and they hold 2.50% of the stock.
Oncolytics Biotech Inc. – Insider Activity and Holdings
As on Mar 31, 2021, International Assets Investment Management, LLC was the top most holder in Oncolytics Biotech Inc. (NASDAQ:ONCY) with an ownership of 0.28 million shares of the company or 0.53% of the stake worth $1.06 million. The filing also reveals Creative Planning as the second largest holder in the company with a control over 0.32% of the outstanding shares. Its stake is worth $0.65 million for having 0.17 million shares in hand.
Two Sigma Advisers, LP also came holding a key position in the company during the recent quarter and it now holds 0.24% of the outstanding shares. With this there are now 44 institutions which have possession in ONCY’s shares.
The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Oncolytics Biotech Inc. was 12.45 while posting a debt to equity ratio of 0.01. The count was 0.62 for long-term debt to equity ratio.
Oncolytics Biotech Inc.’s return on equity, or ROE, is -102.60%, compared to the industry average of -41.93% for Healthcare – Biotechnology. Although this indicates that ONCY fails to use its equity well, the metric will vary significantly depending on the industry.
Technical Analysis of Oncolytics Biotech Inc. (NASDAQ:ONCY) stock
To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Oncolytics Biotech Inc. (ONCY), we notice that the stock’s 20-day average volume is at 602,290 shares and 50% of short term indicators are suggesting the stock as Sell. Medium term indicators at an average of 50% are spotting the stock at Buy with its 50-day average volume of 1,435,914 shares. And to end, ONCY’s 100-day average volume is 1,633,655 shares with 50% of the long-term indicators pointing towards Buy for the stock.